|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
|Leverage (ttm)||Total||- Intang||+ Pension|
|Cash / Assets|
CONMED Corporation is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company is focused on advancing the healing of soft tissue using its proprietary BioBrace Implant technology. The Company's product lines consist of orthopedic surgery and general surgery. Its orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures including dissociated horizontal deviation (DHD) and DHD vision technologies. Its general surgery consists of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. Its products used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology and gastroenterology.
- Curt Hartman CHM (57)
- Todd Garner CFO (52)
- Patrick Beyer CEX (55)
- Daniel Jonas EVP (57)
- Heather Cohen EVP (48)
- Shanna Cotti-osmanski EVP (44)
- Peter Shagory EVP (52)
- John Kennedy VPR (63)
- Stanley Peters VPR (46)
- Terence Berge VPR (51)
- Johonna Pelletier VPR (48)
- Sarah Oliker GCN (44)
- Martha Aronson LED (54)
- David Bronson IND (68)
- Brian Concannon IND (63)
- Laverne Council IND (60)
- Charles Farkas IND (69)
- Jerome Lande IND (45)
- Barbara Schwarzentraub IND (54)
- Mark Tryniski IND (60)
- John Workman IND (69)
Upcoming Events for CNMD
Q3 2022 Conmed Corp Earnings Release
Q4 2022 Conmed Corp Earnings Release
As of Today at 13:05 UTC, shares in Conmed are trading at $103.15. This share price information is delayed by 15 minutes.
Shares in Conmed last closed at $103.15 and the price had moved by -16.5% over the past 365 days. In terms of relative price strength the Conmed share price has underperformed the S&P500 Index by -12.83% over the past year.
The overall consensus recommendation for Conmed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Conmed dividend yield is 0.78% based on the trailing twelve month period.
Last year, Conmed paid a total dividend of $0.80, and it currently has a trailing dividend yield of 0.78%. We do not have any data on when Conmed is to next pay dividends.
We do not have data on when Conmed is to next pay dividends. The historic dividend yield on Conmed shares is currently 0.78%.
To buy shares in Conmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $103.15, shares in Conmed had a market capitalisation of $3.14bn.
Here are the trading details for Conmed:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CNMD
Based on an overall assessment of its quality, value and momentum Conmed is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Conmed is $121.50. That is 17.79% above the last closing price of $103.15.
Analysts covering Conmed currently have a consensus Earnings Per Share (EPS) forecast of $3.31 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Conmed. Over the past six months, its share price has underperformed the S&P500 Index by -24.25%.
As of the last closing price of $103.15, shares in Conmed were trading -19.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Conmed PE ratio based on its reported earnings over the past 12 months is 28.99. The shares last closed at $103.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Conmed's management team is headed by:
- Curt Hartman - CHM
- Todd Garner - CFO
- Patrick Beyer - CEX
- Daniel Jonas - EVP
- Heather Cohen - EVP
- Shanna Cotti-osmanski - EVP
- Peter Shagory - EVP
- John Kennedy - VPR
- Stanley Peters - VPR
- Terence Berge - VPR
- Johonna Pelletier - VPR
- Sarah Oliker - GCN
- Martha Aronson - LED
- David Bronson - IND
- Brian Concannon - IND
- Laverne Council - IND
- Charles Farkas - IND
- Jerome Lande - IND
- Barbara Schwarzentraub - IND
- Mark Tryniski - IND
- John Workman - IND